Digoxin tied to increased risk of death in patients with atrial fibrillation

In An Account of the Foxglove and Some of its Medical Uses, published in 1785, Sir William Withering cautioned readers that extracts from the plant foxglove, also called digitalis, was not a perfect drug. "Time will fix the real value upon this discovery," he wrote.

Now, more than 200 years later, researchers at the Stanford University School of Medicine have validated Withering's warning with the discovery that patients with atrial fibrillation—a rapid and —who are treated with the digitalis-derivative digoxin are more likely to die than similar patients who received different treatments.

"The take-home point is to question whether people should really be on this ," said the study's lead author, Mintu Turakhia, MD, assistant professor of cardiology at Stanford and director of cardiac electrophysiology at the Veterans Affairs Palo Alto Health Care System. "These data challenge the current guidelines."

The study will be published online Aug. 11 in the Journal of the American College of Cardiology, and will appear in the Aug. 19 print issue of the journal.

Turakhia and his team analyzed records from 122,465 patients who received a new diagnosis of atrial fibrillation from the U.S. Department of Veterans Affairs health-care system between 2003 and 2008. Doctors prescribed digoxin to 23 percent of the patients, and 70 percent of those patients were still on the drug one year later. Patients treated with digoxin were 1.2 times more likely to die than comparable patients prescribed other therapies. Patients receiving digoxin were more likely to die regardless of age; use of other drugs such as beta-blockers, amiodarone or warfarin; or the presence of other factors such as kidney disease, heart attack or heart failure, the study found.

"This is going to be as close to proof positive as we get because we may never have a randomized trial of this drug," Turakhia said. Pharmaceutical companies lack the incentive to finance studies on a long-accepted, generic drug.

Although recent studies showed mixed results, doctors and patients trusted digoxin because of its historic status, Turakhia said.

"There's an evidence gap," he said, adding that he launched the investigation because digoxin hasn't been rigorously tested like the many other atrial fibrillation treatment options.

The VA patient pool was predominantly male—only 1,980, or 1.6 percent, were female—and Turakhia has called for additional studies to establish whether the results are applicable to women as well.

Turakhia said many other drugs with better safety results are available to treat atrial fibrillation. Digoxin slows the but does not correct it to a normal rhythm. "We are not asserting this drug should never be used," he said. "However, in light of the many other drugs that can be used to slow down the rate in , and providers need to ask whether should be the treatment of choice when there are other, safer drugs. "

add to favorites email to friend print save as pdf

Related Stories

Popular heart drug may be unsafe for some kidney patients

Jun 24, 2010

For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American So ...

Recommended for you

Study: Removing clot helps limit stroke disability

Dec 17, 2014

For the first time in several decades, a new treatment has been shown to limit the damage from a common type of stroke. Researchers in the Netherlands found that mechanically removing a clot in addition to using a clot-busting ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.